Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMT C1100 (Ezutromid) Phase 1b in Pediatric DMD
NCT02056808Phase 1Completed
- Sponsor
- Summit Therapeutics
- Start
- Nov 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ezutromid in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Summit Therapeutics. Primary endpoint: Safety and tolerability at 10 days. Started Nov 2013; status: completed.
02
Drugs
ezutromid
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02056808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02056808.